Insights

Innovative Product Portfolio POZEN specializes in developing unique, evidence-based integrated therapies, particularly centered around aspirin, which presents opportunities to market healthcare solutions aimed at reducing gastrointestinal side effects, appealing to both patients and healthcare providers seeking safer long-term medication options.

FDA Approval Track Record The company's success in gaining FDA approval for two self-invented products within two years indicates a strong regulatory pathway and a track record of innovative drug development, making it attractive for partnerships or licensing agreements with larger pharmaceutical manufacturers seeking innovative, approved products.

Focus on Unmet Needs POZEN’s commitment to addressing unmet medical needs offers potential sales avenues through targeted marketing to specialty clinics and healthcare providers focused on gastrointestinal health, chronic pain management, and cardiovascular therapies where novel approaches are highly valued.

Growth Potential With a revenue range of $25-$50 million and a relatively small team, POZEN is positioned for strategic partnerships and acquisitions that can accelerate its growth, offering sales opportunities in distribution, licensing, and collaborative research initiatives.

Market Niche Focus Targeting a niche market of integrated, cost-effective pharmacological solutions for common but complex medical issues provides a unique sales proposition, especially in the context of the broader pharmaceutical landscape dominated by large players, highlighting potential for customized business development approaches that emphasize innovation and clinical benefit.

Similar companies to POZEN

POZEN Tech Stack

Media & News

POZEN Inc. to Announce Third Quarter 2015 Results on November 9, 2015
CHAPEL HILL, N.C.--(BUSINESS WIRE)--POZEN Inc. (NASDAQ: POZN) today announced that the Company plans to release results for the third quarter 2015 on Monday, November 9, 2015, before the opening of the U.S. markets. The Company also will conduct a conference call that day at 11:00 a.m. ET to discuss results and highlights of the third quarter of 2015. The presentation slides to be used during the call will be available on the "Investors" section of the Company's website under the "Overview" tab beginning at 11:00 a.m. ET on Monday, November 9, 2015. A live webcast of the conference call, presentation and question and answer session will be available on the "Investors" section of the Company's website under the "Overview" tab. To access the live webcast, please log on to POZEN's site approximately 15 minutes prior to the presentation to register and download any necessary audio software. The presentation replay will be available for 90 days after the event. Conference call details:Date: Monday, November 9, 2015Time: 11:00 a.m. ETDial-in (U.S.): 877-407-8037Dial-in (International): 201-689-8037Webcast: www.pozen.com About POZEN POZEN Inc. is a specialty pharmaceutical company that to date has historically focused on developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products. Funded by these milestones/royalty streams, POZEN has created a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage. POZEN’s common stock is traded under the symbol “POZN” on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit www.pozen.com.
Oct 26, 2015 | www.businesswire.com

POZEN's Email Address Formats

POZEN uses at least 1 format(s):

POZEN Email Formats	Example	Percentage
FLast@pozen.com	JDoe@pozen.com	79%
First.Last@pozen.com	John.Doe@pozen.com	10%
First@pozen.com	John@pozen.com	7%
F.Last@pozen.com	J.Doe@pozen.com	4%

Frequently Asked Questions

Where is POZEN's headquarters located?

POZEN's main headquarters is located at 1414 Raleigh Road, Suite 400. The company has employees across 2 continents, including North AmericaEurope.

What is POZEN's phone number?

You can contact POZEN's main corporate office by phone at

+1-919-913-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is POZEN's stock symbol?

POZEN is a publicly traded company; the company's stock symbol is POZN.

What is POZEN's official website and social media links?

POZEN's official website is pozen.com and has social profiles on LinkedIn.

What is POZEN's SIC code NAICS code?

POZEN's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does POZEN have currently?

As of December 2025, POZEN has approximately 28 employees across 2 continents, including North AmericaEurope. Key team members include Sr. Vp And Cfo: B. H.Svp & General Counsel: G. T.Evp Product Development: M. R.. Explore POZEN's employee directory with LeadIQ.

What industry does POZEN belong to?

POZEN operates in the Pharmaceutical Manufacturing industry.

What is POZEN's email format?

POZEN's email format typically follows the pattern of FLast@pozen.com. Find more POZEN email formats with LeadIQ.

When was POZEN founded?

POZEN was founded in 1996.

POZEN

Q: What is POZEN's official website and social media links?

POZEN's official website is pozen.com. POZEN has social profiles on LinkedIn.

Q: How many employees does POZEN have currently?

POZEN has approximately 28 employees.

Pharmaceutical ManufacturingNorth Carolina, United States11-50 Employees

POZEN Inc., headquartered in Chapel Hill, NC, is a progressive pharmaceutical company committed to transforming medicine that transforms lives. POZEN’s unique in-source business model has been proven through our success in gaining U.S. FDA approval of two self-invented products in two years – something almost no other small pharmaceutical company has achieved. Moving forward, POZEN continues to be dedicated to addressing unmet needs and developing affordable medicines for patients and physicians.

Since our founding in 1996, POZEN has had a long, successful history of creating novel pharmacologic agents by combining existing drug therapies that result in superior patient outcomes. This approach allows for a potentially higher success rate than NCE (new chemical entity) development.